Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity

R A Goodlad, K B Raja, T J Peters, N A Wright

Abstract
The wet weight of the stomach, small intestine, caecum, and colon were significantly reduced (p<0.001) in intravenously fed rats compared with orally fed controls. Human epidermal growth factor (urogastrone) reversed this atrophy. Detailed analysis of the small intestine showed a similar effect on intestinal crypt cell population, mitoses per crypt, and protein content. Brush border γ glutamyltransferase and α glucosidase activities were reduced by up to 50% throughout the small intestine of the animals fed intravenously. The specific activities (mU/mg protein) were unchanged, as a concomitant decrease in the tissue weight and protein content also occurred. Intestinal brush border enzyme activities in the rats treated with urogastrone-epidermal growth factor were restored to those seen in the orally fed rats except for α glucosidase activity in the proximal gut. In addition, the specific activity of γ glutamyltransferase was highly significantly increased (p<0.01) in all regions of the small intestine. Thus, although urogastrone administration prevents the decrease in brush border enzyme activity seen after the removal of luminal nutrition, the response seems to differ depending on the intestinal location, with the specific activities of some enzymes being higher than those seen in orally fed rats. Urogastrone-epidermal growth factor can thus significantly increase the functional ability of the intestine in addition to its trophic effects.

Methods

EXPERIMENTAL PLAN
Three groups of 12 rats (male, 230–240 g Wistar strain) (Olac, Blackthorn, Oxon) were used. The first group was fed on a standard pelleted diet (Labshire PRD), the second on an intravenous diet which was intended to be isocaloric, and the third was given the intravenous diet and urogastrone-epidermal growth factor (60 μg/rat/day). The rats were maintained on the appropriate diet for eight days. The urogastrone was recombinant urogastrone and had the same amino acid sequence and biological activity as natural epidermal growth factor.

INTRAVENOUS NUTRITION
Rats were anaesthetised with intramuscular fentanyl and fluanisone and intraperitoneal diazepam and the right external jugular vein cannulated with silastic cannula. The tubing was tunneled subcutaneously to the back of the neck and connected via a stainless steel skin button and tether to a fluid swivel joint (Scientific Marketing Associates, London) and thence by vinyl tubing to a multichannel peristaltic pump (Watson Marlow, Falmouth, Cornwall). The intravenous diet was stored at 4°C and infused into the rats at 60 ml/rat/day, giving 1.8 g nitrogen, 6.9 g lipid, 8.5 g glucose, and 1047 kJ per kg per day.

NECROPSY PROCEDURE
The animals were anaesthetised with pento-barbitone and killed by exsanguination. The entire gastrointestinal tract was removed, rinsed with ice cold 0·15 mol/l NaCl, blotted, and weighed. Two centimetre lengths of small intestine were cut from sites 10, 50, and 90% from the proximal end of the small intestine. The segments of intestine were weighed, placed in 2 ml of ice cold 20 mmol/l hydroxyethylpiperazine ethanesulphonic acid 0·15 mol/l NaCl buffer (pH 7·4), and homogenised in a glass Dounce Homogeniser (Kontes Glass, Vineland, NJ, USA). The homogenate was stored frozen at −20°C until analysis.

BIOCHEMICAL ASSAYS
α Glucosidase (EC 3.2.1.20) and γ glutamyltransferase (EC 2.3.2.2) activities were measured fluorimetrically by the methods of Peters and Smith et al respectively. An aliquot of intestinal homogenate of suitable
Effects of urogastrone-epidermal growth factor on intestinal brush border enzymes and mitotic activity

Organ weights in orally fed, intravenously fed (TPN), and TPN plus urogastrone-epidermal growth factor (URO-EGF) treated rats (mean (SEM))

<table>
<thead>
<tr>
<th></th>
<th>Orally fed (n=12)</th>
<th>TPN (n=12)</th>
<th>TPN + URO-EGF (n=12)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Initial weight (g)</td>
<td>230 (3)</td>
<td>239 (3)</td>
<td>241 (4)</td>
</tr>
<tr>
<td>Final weight (g)</td>
<td>289 (4)</td>
<td>224 (3)*</td>
<td>219 (4)</td>
</tr>
<tr>
<td>Stomach weight (g)</td>
<td>1.73 (0.04)</td>
<td>1.15 (0.03)*</td>
<td>1.63 (0.03)†</td>
</tr>
<tr>
<td>Small intestine weight (g)</td>
<td>10.5 (0.3)</td>
<td>4.9 (0.1)*</td>
<td>7.7 (0.2)†</td>
</tr>
<tr>
<td>Caecum weight (g)</td>
<td>1.37 (0.06)</td>
<td>0.86 (0.36)*</td>
<td>1.37 (0.07)†</td>
</tr>
<tr>
<td>Colon weight (g)</td>
<td>1.88 (0.06)</td>
<td>0.91 (0.03)*</td>
<td>2.02 (0.08)†</td>
</tr>
<tr>
<td>Small intestine length (cm)</td>
<td>125 (2)</td>
<td>110 (1)*</td>
<td>111 (1)</td>
</tr>
<tr>
<td>Colon length (cm)</td>
<td>20.0 (0.3)</td>
<td>13.2 (0.2)</td>
<td>15.3 (0.4)†</td>
</tr>
</tbody>
</table>

*p<0.001, †p<0.0001 compared to the TPN group.

Statistical analysis

**Results**

The orally fed rats gained weight, while the rats fed intravenously lost weight (Table). The weight of the stomach, small intestine, caecum, and colon were significantly reduced (p<0.001) after intravenous feeding. The reduction in intestinal weight as well as in stomach, caecum, and colon weight was, however, prevented by concomitant urogastrone-epidermal growth factor administration. Due to the apparent differences in body weight between the three groups, the relative weights of the stomach, caecum, and colon (expressed as a per cent of body weight) were significantly (p<0.001) heavier in the group receiving a combination of intravenous feeding and urogastrone than the orally fed group (Fig 1). The length of the small intestine was decreased in the group fed intravenously and was little changed by urogastrone treatment. The colon was appreciably shorter after intravenous feeding but was significantly lengthened after urogastrone administration.

The crypt length (cell column count) was reduced (p<0.001) in the rats fed intravenously (Fig 2) and was restored to normal levels when urogastrone was administered. Intravenous feeding of the animals also resulted in over a 30% reduction in the crypt diameter, this being partially restored with urogastrone treatment (Fig 2). Consequentially, the crypt cell population in the third group, although significantly greater than in the group fed intravenously (p<0.001) was less than that seen in the orally fed rats (p<0.01). No significant changes in Tannock's factor were observed in the experimental groups (mean (SEM) orally fed 0.447 (0.031), intravenous 0.479 (0.006), intravenous + urogastrone 0.466 (0.014)). The mitotic index was reduced to a small extent by parenteral nutrition, but as the denominator for this index had also decreased the number of mitoses per crypt column and per crypt was significantly decreased (p<0.01). All measures of mitotic activity were increased to normal levels by urogastrone treatment (Fig 2).

A similar pattern was also seen in the weight of...
the isolated intestinal segments (Fig 3). The protein content of the tissue samples obtained from the three regions of the gut was also significantly reduced in the group fed intravenously. The values were likewise significantly increased by the urogastrone administration, though not to the same extent as with the weights (compare Fig 3 top and bottom). Brush border \( \alpha \) glucosidase and \( \gamma \) glutamylntransferase activities (mU/cm gut) were reduced by 25–50% in all regions of the small intestine of the intravenously fed animals compared with the orally fed group (Figs 4 and 5, top). Enzyme activity was restored to the levels seen in orally fed animals after urogastrone administration, with the exception of \( \alpha \) glucosidase in the proximal intestine. When enzyme activities were expressed as specific activity (mU/mg protein), no significant changes were seen in any of the three intestinal regions of the group fed intravenously compared with oral values (Figs 4 and 5, bottom). This observation is attributable to the fact that the intestinal protein content decreased by a similar amount in all three intestinal regions during intravenous feeding (Fig 3, bottom). Furthermore, \( \alpha \) glucosidase specific activities were not significantly altered after concomitant urogastrone administration. In contrast, the specific activity of \( \gamma \) glutamylntransferase was increased in all regions after urogastrone administration compared with values in either the intravenously or the orally fed groups (Fig 4, bottom).

**Discussion**
The proliferative effects of urogastrone-epidermal growth factor were confirmed in the present experiment, especially when the weight increase of the orally fed group was taken into account. Although the proliferative response was evident in the small intestine, it was generally less pronounced than that in other regions of the gastrointestinal tract. This may be due to differences in the susceptibility of the organs to the effects of urogastrone. There has also been recent evidence of the colon having considerably more epidermal growth factor receptors than the small intestine. Data for the caecum and stomach are not available.

Morphometric analysis of the small intestinal mucosa showed that the crypt length was significantly reduced by intravenous feeding and restored by urogastrone treatment. The crypt cell population values, however, seemed not to be fully restored in the group receiving intravenous feeding + urogastrone due to the incomplete recovery of the crypt diameter. The crypt
feeding, intravenous factor and small intestine. Weight and greater feeding, the intestine were expressed per unit length. Significantly greater than the TPN group: \(^*p<0.05\), \(**p<0.01\), \(***p<0.001\).

cell population data showed remarkable similarities to the small intestinal weight and protein data. The changing crypt cell population would explain the lack of a noticeable decrease in mitotic index, and again shows the importance of choosing the correct denominator. A similar lack of proliferative activity was first seen in our studies on the actions of prostaglandins on the stomach, but as the length of the gastric glands were also increased, the proliferative activity and gland cell production were in fact appreciably increased.

The activities of both \(\alpha\) glucosidase and \(\gamma\) glutamyltransferase fell greatly with intravenous feeding. The absence of a change in the specific activity with such feeding suggests that the decrease in enzyme activity is a consequence of intestinal atrophy. The activity of both enzymes was restored to normal after urogastrone treatment, with the exception of the proximal intestinal \(\alpha\) glucosidase. The lack of response in the proximal region indicates that 'luminal nutrition' may be particularly important for the maturation of \(\alpha\) glucosidase. Discrepancies in the enzyme activities were, none the less, more evident when values were expressed as mU/mg protein: \(\gamma\) glutamyltransferase showed a significant increase in all regions after urogastrone administration, while \(\alpha\) glucosidase specific activities were moderately decreased or unchanged compared with values in the group fed intravenously. These differences may be a function of the intestinal localisation of the enzymes: \(\alpha\) glucosidase activity is relatively constant along the villus while \(\gamma\) glutamyltransferase shows a pronounced gradation in activity along the villus, with peak activity at the tip. The increased specific activity could thus be the consequence of either decreased cell loss at the villus tip or a downward migration of the functional zone of the villus. The magnitude of the increase in mitoses per crypt was greater than that of the cell population, suggesting that the influx of cells into the villus was indeed greater. Alteration in villus function, which can be attributed to the influx of cells from the crypt, even at the expense of maintaining the crypt cell population, has been observed in models of starvation and refeeding.

Several studies have now shown that epidermal growth factor can stimulate proliferation and maturation of the neonatal rodent intestine\(^5\) and fetal human jejunum.\(^6\) The hormone may act either luminally or systemically, as it can pass through the intestine of suckling and weaning rats.\(^7\) Data on the adult are scarce, but it has recently been reported that both systemic and luminal epidermal growth factor infusion can stimulate galactose and glycine absorption from Thiry-Vella loops,\(^8\) and the administration of physiological doses to mature mice can enhance mucosal iron absorption.

While the specific enzyme activity is a useful measure of intestinal maturity and function, the activity available per unit gut length is the most relevant physiologically with respect to nutrient absorption, and as no difference in gut length was noted between the groups fed intravenously and intravenously + urogastrone, it can be concluded that as well as increasing mucosal mass, urogastrone-epidermal growth factor appreciably increased the ability of the adult small intestine to perform its digestive functions.

We thank Dr H Gregory of ICI Pharmaceuticals, Alderley Park, Macclesfield, for the gift of the urogastrone and acknowledge the technical assistance of Mr W Lennon.
Goodlad, Raja, Peters, Wright